{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:56:21Z","timestamp":1753890981164,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>COVID-19 is characterized by a severe pulmonary disease due to severe acute respiratory syndrome (SARS)-CoV-2 infection. For clinicians involved in the management of patients with chronic autoimmune diseases the risk linked to the conditions itself and to drug-induced immunosuppression during the COVID-19 pandemic is a major topic. Pemphigus is a rare autoimmune blistering disease (AIBD) of the skin and mucous membranes caused by autoantibodies to desmosomal components, desmoglein 1 and 3. Among immunosuppressant therapies, rituximab (RTX) is considered a highly effective treatment with a favorable safety profile, but it induces a prolonged B-cell depletion that can lead to higher susceptibility to infections. For this reason, concerns about its use during the pandemic have been raised. We describe a case of a pemphigus patient in which RTX-induced\u00a0B cell depletion led to the severe inflammatory phase, whereas corticosteroid treatment allowed a favorable outcome.<\/jats:p>","DOI":"10.3389\/fimmu.2021.665522","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:44:58Z","timestamp":1618598698000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab"],"prefix":"10.3389","volume":"12","author":[{"given":"Jo Linda","family":"Sinagra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Vedovelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Binazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"Salemme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Moro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Mazzanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biagio","family":"Didona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Di Zenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.04.005","article-title":"Treatment considerations for patients with pemphigus during the COVID-19 pandemic","volume":"82","author":"Shakshouk","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217424","article-title":"Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies","volume":"79","author":"Monti","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1136\/annrheumdis-2020-217615","article-title":"What is the true incidence of COVID-19 in patients with rheumatic diseases","volume":"80","author":"Favalli","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.05.001","article-title":"Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs","volume":"52","author":"Michelena","year":"2020","journal-title":"Semin Arthritis Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: Current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17207","article-title":"Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.1111\/dth.14398","article-title":"Aggressive course of pemphigus vulgaris following COVID-19 infection","volume":"33","author":"Ghalamkarpour","year":"2020","journal-title":"Dermatol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0976-5","article-title":"Targeted Therapies for Autoimmune Bullous Diseases: Current Status","volume":"78","author":"Amber","year":"2018","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts","volume":"82","author":"Murrell","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e14265","DOI":"10.1111\/dth.14265","article-title":"Pemphigus and COVID-19: Critical overview of management with a focus on treatment choice","volume":"33","author":"Elmas","year":"2020","journal-title":"Dermatol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.043","article-title":"Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study","volume":"14","author":"Mahmoudi","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2020.1789041","article-title":"COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience","author":"Shahidi-Dadras","year":"2020","journal-title":"J Dermatol Treat"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e14647","DOI":"10.1111\/dth.14647","article-title":"Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic","volume":"34","author":"Uzuncakmak","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.16.20023903","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"B17","first-page":"75","article-title":"Evolution of pulmonary pathology in severe acute respiratory syndrome","volume":"104","author":"Hsiao","year":"2005","journal-title":"J Formos Med Assoc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323279111","article-title":"Rapid generation of a mouse model for Middle East respiratory syndrome","volume":"111","author":"Zhao","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.633815","article-title":"Corrigendum: Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients (Front. Immunol., (2020), 11, (582010), 10.3389\/fimmu.2020.582010)","volume":"11","author":"Niu","year":"2020","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071140","article-title":"Age-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus","volume":"205","author":"Yager","year":"2008","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1038\/s41467-021-21702-6","article-title":"Deciphering the state of immune silence in fatal COVID-19 patients","volume":"12","author":"Bost","year":"2021","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.631226","article-title":"In fl ammation and Antiviral Immune Response Associated With Severe Progression of COVID-19","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12932\/AP-200220-0772","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pacific J Allergy Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2146","article-title":"Predictors of COVID-19 severity: A literature review","volume":"31","author":"Gallo Marin","year":"2021","journal-title":"Rev Med Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26031","article-title":"The value of clinical parameters in predicting the severity of COVID-19","volume":"92","author":"Shang","year":"2020","journal-title":"J Med Virol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"108509","DOI":"10.1016\/j.clim.2020.108509","article-title":"Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy","volume":"217","author":"Ciceri","year":"2020","journal-title":"Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2001112","DOI":"10.1183\/13993003.01112-2020","article-title":"Association between age and clinical characteristics and outcomes of COVID-19","volume":"55","author":"Liu","year":"2020","journal-title":"Eur Respir J"},{"key":"B29","article-title":"Randomised Evaluation of Covid-19 Therapy (RECOVERY)","author":"Horby","year":"2020","journal-title":"EudraCT"},{"key":"B30","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1101\/2020.06.22.20137273","article-title":"Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report","volume":"384","author":"Horby","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17022","article-title":"Effect of Hydrocortisone on Mortality and Organ Support in Patients with Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial","volume":"324","author":"Angus","year":"2020","journal-title":"JAMA J Am Med Assoc"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16491","article-title":"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases","volume":"34","author":"Di Altobrando","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.012","article-title":"COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases","volume":"84","author":"Kasperkiewicz","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.075","article-title":"Toward a COVID-19 vaccine strategy for patients with pemphigus on rituximab","volume":"84","author":"Waldman","year":"2021","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.665522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:45:00Z","timestamp":1618598700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.665522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2021.665522"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.665522","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"article-number":"665522"}}